转移性结直肠癌抗血管生成靶向治疗的研究进展

The Research Progress of Anti-angiogenesis Targeted Therapy for Metastatic Colorectal Cancer

结直肠癌是一种发病率及病死率较高的肿瘤,约20%的患者就诊时已经出现转移,20%~25%的患者随着疾病的进展也会出现转移。转移性结直肠癌（m CRC）5年存活率较低。近年来,随着对肿瘤细胞信号转导途径及肿瘤血管生成机制等研究的不断深入,分子靶向药物已经成为治疗m CRC最有效的手段之一,尤其是抗血管生成药物在m CRC的治疗中取得了较好的疗效,该文汇总了抗血管生成药物在m CRC中的应用进展,同时,剖析了目前存在的主要问题。

Colorectal cancer is one of the tumor types with the highest incidence and mortality. About 20% of the patients with colorectal cancer have had metastatic cancer when they see a doctor,and 20% -25% of the patients will suffer metastatic cancer with progression of the disease. At present,5-year survival rate of metastatic colorectal cancer（mCRC） is still low. In recent years, the molecular targeted drugs have become one of the most effective means of treatment of mCRC,especially anti-angiogenesis drugs have obtained good effects in the treatment of mCRC with continuously intensive study in signal transduction pathways of tumor cell and mechanism of tumor angiogenesis. Here is to summarize the application progress of anti-angiogenesis drugs in mCRC and analyze the main existing problems.